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Inference for the median residual life
function in sequential multiple
assignment randomized trials
Kelley M. Kidwell,a*† Jin H. Kob and Abdus S. Wahedc
In survival analysis, median residual lifetime is often used as a summary measure to assess treatment effective-
ness; it is not clear, however, how such a quantity could be estimated for a given dynamic treatment regimen
using data from sequential randomized clinical trials. We propose a method to estimate a dynamic treatment
regimen-specific median residual life (MERL) function from sequential multiple assignment randomized tri-
als. We present the MERL estimator, which is based on inverse probability weighting, as well as, two variance
estimates for the MERL estimator. One variance estimate follows from Lunceford, Davidian and Tsiatis’ 2002
survival function-based variance estimate and the other uses the sandwich estimator. The MERL estimator is
evaluated, and its two variance estimates are compared through simulation studies, showing that the estimator
and both variance estimates produce approximately unbiased results in large samples. To demonstrate our meth-
ods, the estimator has been applied to data from a sequentially randomized leukemia clinical trial. Copyright ©
2013 John Wiley & Sons, Ltd.
Keywords: dynamic treatment regimen; adaptive treatment strategy; inverse probability weighting; median
residual life function; sequential randomization; non-parametric estimation
1. Introduction
Patients are often interested in a summary measure of their prognosis or survival throughout treatment.
At diagnosis, physicians may explain the benefit of a particular treatment by giving an estimate of the
patient’s expected survival he/she receives that treatment. Physicians may choose to present the sur-
vival estimates based on Kaplan–Meier curves from large randomized controlled trials by the mean or
median time depending on the nature of the data. Patients are likely to request updated survival times
as they progress through their treatment(s), such that if they have already survived to some point, they
may be interested in their residual life expectancy following a particular treatment plan. These residual
estimates are of increasing importance as newer and more personalized treatments become available
and as physicians tailor sequences of treatments to individuals over time. As treatment becomes more
personalized and sequential such that subsequent treatment may depend on the individual’s response to
previous treatment, on the course of the individual’s disease, or on characteristics or behaviors of the
individual, patients and physicians have particular interest in the residual lifetime of the entire treatment
regimen, not just the last treatment in an individualized sequence.
Sequences of treatments tailored to the individual are called dynamic treatment regimens (DTRs), also
known as adaptive treatment strategies. DTRs are particularly valuable for treating chronic diseases, such
as cancer, depression, and AIDS, where treatment is frequently modified to adapt to patients’ health sta-
tus. The concept of DTRs is motivated by the fact that when patients take one treatment after another,
especially in the setting of chronic diseases, it is often the entire sequence of treatments which yields the
overall outcome, not just the most recent treatment.
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To elaborate on the concept of DTRs and illustrate the difference between comparing treatments at
one stage in the disease process (local comparison) and comparing sequences of treatments through-
out the disease process (global comparison), consider the setting of acute myeloid leukemia (AML).
DTRs are particularly suitable in the treatment of AML due to two main questions of interest: (i) should
induction chemotherapy be followed with a growth factor infusion, and (ii) if a patient achieves remis-
sion, should maintenance therapy consist of a mono-therapy or combination therapy. These questions
have been addressed locally by comparing survival between treatment groups at specific stages of the
disease/trial. We can construct DTRs including the first and second stage treatments, as well as, the
intermediate remission status and then ask global questions, such as what is the best treatment regimen
to achieve the best overall survival.
To construct a DTR, we put the stages of treatment and any intermediate decisions together. An exam-
ple of a DTR in the treatment of AML is ‘Treat the patient with induction chemotherapy and add a growth
factor; if remission is achieved, treat with a combination of maintenance therapies; if remission is not
achieved, declare a treatment failure.’ Another regimen may be stated in the same way, but eliminating
the growth factor. Thus, regimens are not just a sequence of treatments, but they also contain a decision
rule based on individual characteristics or response that dictates specific treatments (or lack thereof) in
the sequence. Estimation of the entire DTR, including the initial treatment, response, and maintenance
therapy, is of interest to find the best global treatment for a patient.
Locally, in the treatment of AML, there are two comparisons, where the first consists of comparing
induction treatments of chemotherapy alone versus chemotherapy plus a growth-stimulating factor, and
the second consists of comparing maintenance treatments of mono-therapy versus combination therapy.
The local comparisons may shine light on the best treatment at that stage for a specific group of people,
but combining the conclusions from the two local comparisons may not be the best globally. For exam-
ple, the best first-stage treatment for achieving remission may not produce the best extended survival
(perhaps the first-stage treatment was so strong or produced toxicities so that the maintenance treatment
could not be tolerated). Moreover, the best maintenance treatment discovered in isolation may act syner-
gistically or antagonistically with a particular first-stage treatment. Because the treatment would likely
be prescribed and followed as a DTR in practice and we are ultimately interested in the overall result, it
is important to estimate and compare the effect of DTRs. A global metric for identifying the best DTR
for AML or any chronic disease may be the expected residual lifetime at a specific time (e.g., one year).
Sequential multiple assignment randomized trials (SMARTs) [1, 2] are designed to follow patients
over time, develop, and potentially compare DTRs. In SMARTs, patients are randomized to treatment
options and re-randomized to move from one stage to another as the trial progresses. Figure 1 shows
an example of a two-stage SMART from the Cancer and Leukemia Group B (CALGB) co-operative
group for the treatment of leukemia [3, 4]. At entry, patients were randomized to one of the two first-
stage treatments, standard chemotherapy (A1) or standard chemotherapy plus granulocyte-macrophage
colony-stimulating factor (GM-CSF, A2). If the patient achieved complete remission, he or she was ran-
domized to one of the second-stage treatments, cytarabine (B1) or cytarabine plus mitoxantrone (B2).
Because this trial was conducted in a sample of elderly patients, the treatment was considered a failure if
remission was not achieved and no further treatment was provided. This SMART contains four embed-
ded DTRs AjBk , j; k D 1; 2, where the DTR AjBk is defined as ‘Treat with Aj followed by Bk if a
response to Aj is observed, otherwise there is no further treatment’ [5]. Note that a patient belonging to
either of the following two scenarios is considered to be treated (or consistent) with DTR AjBk :
(1) patient received Aj and did not respond and,
(2) patient received Aj , responded, and received Bk at the second-stage.
Throughout such a trial, or more generally, throughout treatment, physicians and patients are inter-
ested in an easy to understand summary measure of benefit. For survival analysis, patient benefit is
frequently measured by the survival probability or often by the sample mean or median survival time.
The estimation of mean survival time in a SMART, mainly in two-stage designs, has been studied
extensively in statistical literature. Lunceford, Davidian and Tsiatis (LDT) [5] proposed estimators for
the survival distribution and mean restricted survival time of different treatment regimens using the con-
cept of inverse probability weighting [6]. By including additional information from auxiliary covariates,
Wahed and Tsiatis [7, 8] improved upon the efficiency of such estimators presenting locally efficient
estimators for complete and right-censored cases. Guo and Tsiatis [9] proposed an easier to compute and
1504
Copyright © 2013 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1503–1513
K. M. KIDWELL, J. H. KO AND A. S. WAHED
Figure 1. An example of sequential multiple assignment randomized trial from Cancer and Leukemia group B
including four embedded dynamic treatment regimens.
efficient weighted risk set estimator to summarize survival distributions of DTRs using time-dependent
weights and the Nelson–Aalen estimator.
The aforementioned methods summarized survival distributions from SMARTs using estimated pop-
ulation means, but this measure is not always the best summary. The sample mean is not necessarily
representative of the overall survival distribution when data are highly skewed. In such cases, percentiles,
including the median, are more useful to outline survival distributions. The median residual life (MERL)
function is frequently used as an alternative to the mean summary of time-to-event data. The MERL
estimate at a given time point addresses patients’ and physicians’ request for an updated synopsis of
survival, given that the patient has survived up to that point.
The MERL function is the median of the remaining lifetime at a specific time point, and its estimation
and comparison between two groups have been well researched in standard one-stage trials. For overall
survival T , the median residual lifetime at time t0 is defined as
.t0/ D median.T  t0jT > t0/;
where median.X jY / stands for the median of the conditional distribution of X given Y . In other words,
.t0/ is the median survival time for those who survived beyond time t0 in the population. The MERL is
stable because it is not affected by outliers (such as extended durations of survival time). In the case of
censored data, using the median residual lifetime not only exhibits a better location estimate than using
the mean, but it also shows less sensitivity to skewed distributions. In order for the MERL to be defined
under censoring at least half of those remaining must have observed failure times [10].
Various methods have been proposed to estimate median residual lifetimes for one and two sample
cases for one-stage randomized clinical trials. Haines and Singpurwalla [11] introduced the general con-
cept of the ˛-percentile residual life function (0 < ˛ < 1). This concept was discussed and expanded
upon in Arnold and Brokett [12], Joe and Proschan [13], Joe [14], and Song and Cho [15]. Csorgo and
Csorgo [16] proposed a 100.1  p/th percentile residual lifetime estimator for complete data, whereas
Chung [17] incorporated censoring. A non-parametric estimator of the 100.1  p/th percentile resid-
ual lifetime was proposed by Feng and Kulasekera [18] using an inverse function of the Kaplan–Meier
curve. Lillo [19] provided a thorough background of statistical literature related to the MERL function,
offered a different approach from Joe and Proschan [13] to characterize the family of distributions, and
explored relationships between the analytical properties of survival and MERL functions. These meth-
ods, however, cannot be applied to estimate regimen-specific median residual lifetimes in two-stage
SMART designs because they do not account for the sequential randomization structure.
The MERL function has not been estimated in the setting of SMARTs and development of DTRs. In
this paper, we develop a method for the non-parametric estimation of a regimen-specific MERL function
from two-stage sequential randomization trials which can be generalized to the estimation of percentiles
other than the median. The method utilizes marginal mean models for survival data introduced by LDT
Copyright © 2013 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1503–1513
1505
K. M. KIDWELL, J. H. KO AND A. S. WAHED
[5]. Section 2 describes the notation used throughout this article. Section 3 develops the MERL func-
tion estimate and two corresponding variance estimate methods. Section 4 presents simulation studies
demonstrating the performance of our proposed method and variance estimates. Section 5 applies the
method to the CALGB leukemia data set to estimate the MERL function of four DTRs. We conclude
with a discussion in Section 6.
2. Notation and assumptions
To estimate the MERL function of DTRs, we consider the two-stage design described in the previous
section. The development of our method uses the concept of counterfactual variables [20] borrowed from
causal inference literature. To introduce this concept and our notation, consider only the population that
receives the initial treatment A1 (development for the population receiving A2 is analogous). For the
i th individual in the population, let Ri be the observed response indicator: Ri D 1 if patient i responds
to the first-stage treatment A1, Ri D 0 otherwise. If patient i did not respond, his or her survival time
is denoted by TNRi . If patient i responded and received maintenance treatment Bk , his or her time to
the start of the second-stage treatment is denoted by TRi and his or her post-response (or post-start-of-
second-stage) survival time is denoted by T 
ki
. Therefore, under the DTR A1Bk , the overall survival time
for patient i can be defined as
Tki D .1  Ri /TNRi C Ri .TRi C T ki /; k D 1; 2:
Note that, TNRi , T1i , and T2i cannot all be observed for the same patient because patient i either did not
respond to the initial treatment and therefore did not receive any maintenance therapy (Tki D TNRi ,
k D 1; 2), or patient i responded and received only one of the two maintenance therapies, B1
(T1i D TRi C T 1i ) or B2 (T2i D TRi C T 2i ). These variables, T1i and T2i , are referred to as coun-
terfactuals or potential outcomes [20]. Counterfactuals include the set of all possible outcomes, in this
case survival times, including those which we observe and those which we do not.
Our interest lies in estimating the MERL function for DTR A1Bk , k D 1; 2, or equivalently, the
MERL function for the overall survival Tki . Now, if the survival time for the i th patient, Ti , is observed,
it can be expressed in terms of T1i and T2i by means of the consistency assumption [21], such that,
Ti D Z1iT1i C Z2iT2i , where Zki , k D 1; 2, is the Bk treatment assignment indicator, i.e., Zki D 1 if
the i th patient was assigned to treatment Bk , 0 otherwise. Alternatively, Ti can be expressed as,
Ti D .1  Ri /TNRi C Ri .TRi C Z1iT 1i C Z2iT 2i /:
However, because of censoring, Ti may not necessarily be observed. The observed data from a two-stage
design similar to that described in Figure 1 can be denoted by (Ri ; RiZki ; Ui ; i ), i D 1 : : : n; k D 1; 2,
where Ri and Zki are defined previously, i is the complete case indicator, and Ui is the event (survival
or censoring) time. If Ci is used to denote the censoring time for the i th individual in the sample, then
Ui D min.Ti ; Ci / and i D I.Ti < Ci /. Note that, in practice, patients may be censored prior to observ-
ing a response; such patients are historically treated as non-responders in the analysis. We assume that
censoring does not depend on Ti or any other observed or counterfactual data.
Let K.t/ be the survival distribution function of censoring time Ci , i.e., K.t/ D P.Ci > t / and let
1 D P.Z1i D 1jRi D 1/ and 2 D 1  1 denote the probability of receiving treatment B1 or B2,
respectively. Further, let Sk.t/ D P.Tk > t/ denote the survival probability at time t under regimen
A1Bk for k D 1; 2. Then, our goal is to find an estimator of the MERL under DTR A1Bk for k D 1; 2
k0 D k.t0/ D median.Tk  t0jTk > t0/: (1)
3. Estimation of the median residual life function
3.1. Median residual life estimator
We first express k0 as a function of Sk.t0/ so that the median residual lifetime can be indirectly
estimated from the estimated survival curve. The MERL defined in Equation (1) can be equivalently
expressed as P.Tk  t0 > k0jTk > t0/ D 12 , thereby suggesting that k0 D S1k

1
2
Sk.t0/
  t0, where
S1
k
.u/ is the inverse of the survival function at u, i.e., S1
k
.u/ D infŒt W Sk.t/ < u.
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Thus, if we consistently estimate the survival distribution Sk.t0/ by OSk.t/ [18, 22], we can estimate
k0 by
Ok0 D OS1k

1
2
OSk.t0/

 t0: (2)
This method of estimation is valid as long as OS1
k
.t/ exists at t D 1
2
OSk.t0/.
To consistently estimate the survival curve for a given DTR A1Bk , k D 1; 2, we use the
weight-normalized inverse probability-weighted estimator from Lunceford, Davidian, and Tsiatis [5]
defined as:
OSk.t0/ D

nP
iD1
iQki
OK.Ui /
1  nP
iD1
iQki
OK.Ui / I.Ui > t0/

; (3)
where OK.Ui / is the Kaplan–Meier estimator of K.t/ and Qki D 1  Ri C RiZkik is the weight function.
In estimating the survival function Sk , every uncensored survival time Ui is weighted by 1K.Ui / to reflect
the fact that there were P.Ci6Ui /
P.Ci>Ui /
D 1
K.Ui /
1 expected censored individuals in the population at time Ui .
Therefore, an uncensored individual counts for himself or herself and 1
K.Ui /
1 additional censored indi-
viduals. The weight function, Qki , assigns each observation the appropriate weight consistent with DTR
A1Bk , k D 1; 2. More specifically, Qki is defined to reflect that patients who do not respond to A1 are
consistent with both DTRs A1B1 and A1B2, and only a portion of patients who respond are treated with
A1B1 (A1B2) with randomization probability 1 (2). Thus, for the treatment regimen A1B1, Q1i D 0
if individual i responded to A1 and received B2 (i.e., Ri D 1 and Zi D 0), Q1i D 1 if individual i did
not respond to A1 (Ri D 0), and Q1i D 11 if individual i responded to A1 and received B1 (Ri D 1
and Zi D 1). Similarly, Q2i acts as the weight when an individual receives treatment consistent with
DTR A1B2.
By using this consistent estimate of the survival function for each DTR, we obtain the estimator of
the MERL function, Ok0, by substituting Equation (3) in Equation (2). In the remaining subsections, we
propose two different methods for estimating the variance of k0.
3.2. Lunceford, Davidian and Tsiatis variance estimator
The first variance estimator follows directly from the survival function-based variance estimator from
LDT [5]. We mention again that Ok0 satisfies
OSkŒt0 C Ok0  1
2
OSk.t0/ D 0: (4)
Let us denote the left hand side of Equation (4) by OMk. Ok0/. This quantity, OMk. Ok0/, is a random vari-
able even if k0 is known due to the estimated survival function OSk.t/. Expanding OMk. Ok0/ around k0,
we obtain,
OMk. Ok0/  OMk.k0/ C . Ok0  k0/@
OMk.k0/
@k0
:
Assuming sufficient regularity, it follows that variance of Ok0 can be approximated by
var. Ok0/  varŒ
OMk.k0/
E
h
@ OMk.k0/
@k0
i2 :
Note that @ OMk./
@
D  Ofk.t0 C /, leading to
var. Ok0/  varŒ
OMk.k0/
Of 2
k
.t0 C k0/
; (5)
where fk./ is the density function of Tk , which can be estimated by using an inverse probability-
weighted non-parametric smoothing technique such as the kernel density estimator.
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To estimate the variance in the numerator in Equation (5), note that OMk.k0/ can be written as
nP
iD1
iQkiOK.Ui /
1  nP
iD1
iQkiOK.Ui / h.Ui I k0/

; (6)
where h.Ui I / D I.Ui > t0 C/ 12I.Ui > t0/. This is very similar to the survival function estimate in
LDT [5] presented in Equation (3) except that I.Ui > t0/ is replaced by h.Ui I k0/. They show that the
estimator OSk.t0/ defined by Equation (3) is a consistent and asymptotically normal estimator with mean
Sk.t0/ and variance 2k .t0/, that can be estimated by
O2k .t0/ D
1
n
(
1
n
nX
iD1
i
OK.Ui /
h
QkiI.Ui > t0/  OSk.t0/
i2 C Z L
0
dN c.u/
OK.u/Y.u/
OEŒLki .t; u/2
)
;
where,
OEŒLki .t; u/2 D 1
n
nX
iD1
i
n
Qki
h
I.Ui > t0/  OSk.t0/
i
 OGk.t; u/
o2 I.Ui > u/
OK.Ui /
and
OGk.t; u/ D 1
n OS.u/
nX
iD1
iQki
h
I.Ui > t0/  OSk.t0/
i I.Ui > u/
OK.Ui /
:
Here, N c.u/ D PniD1 N ci .u/ D PniD1 I.Ui 6 u;i D 0/ and Y.u/ D PniD1 Yi .u/ D PniD1 I.Ui > u/.
A similar derivation can be used to obtain the variance estimator of the variance of OMk.k0/, namely,
varŒ OMk.k0/ D1
n
(
1
n
nX
iD1
i
OK.Ui /
h
Qkih.Ui I Ok0/  OMk. Ok0/
i2
C
Z L
0
dN c.u/
OK.u/Y.u/
OEŒLki .t; u/2
)
;
(7)
where
OEŒLki .t; u/2 D 1
n
nX
iD1
i
h
Qkifh.Ui I Ok0/  OMk. Ok0/g  OGk.t; u/
i2 I.Ui > u/
OK.Ui /
and
OGk.t; u/ D 1
n OS.u/
nX
iD1
iQkifh.Ui I Ok0/  OMk. Ok0/gI.Ui > u/OK.Ui /
:
Equation (7), along with an inverse probability-weighted kernel density estimator of fk , can then be used
in Equation (5) to produce a variance estimator of Ok0, which we refer to as the LDT variance estimator.
3.3. Sandwich variance estimator
To derive the second variance estimator of k0, note that the MERL estimator given in Equation (2)
using the consistent estimate of survival provided in Equation (3) is equivalent to directly solving an
appropriate estimating equation of the form
nX
iD1
gi .k0/ D 0; (8)
where gi .k0/ D iQkiK.Ui / ŒI.Ui > t0Ck0/ 12I.Ui > t0/, and K./ is unknown and must be consistently
estimated (we use the Kaplan Meier estimator OK.Ui /).
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On the basis of this representation of Ok0, an alternative method to estimating the variance of k0
is to use the sandwich estimator (Stefanski and Boos [23]). Because gi .k0/ is not a smooth func-
tion, the sandwich variance is given by, var.k0/ D n1A.k0/1B.k0/ŒA.k0/1T , where A.k0/ D
 @
@k0
EŒg.k0/ and B.k0/ D EŒg.k0/g.k0/T . To estimate these quantities and, hence, the vari-
ance of Ok0, we replace A./ and B./ by their empirical counterparts and obtain the sandwich variance
estimator
var. Ok0/ D Bn.
Ok0/
nŒAn. Ok0/2
; (9)
where An. Ok0/ D  Ofk.t0 C Ok0/ and Bn. Ok0/ D
hPn
iD1
iQki
OK.Ui /
i1 Pn
iD1 Œgi . Ok0/2.
4. Simulation study
We conducted simulation studies to evaluate the proposed MERL estimator and to compare the LDT and
sandwich variance estimators. The simulations were designed for the induction treatment A1. Because
initial treatment A1 or A2 is assigned by randomization, results for DTRs beginning with A2 are analo-
gous. We generated n independent sets of observations as follows. An indicator of the patient’s response,
Ri , was generated from a Bernoulli (R) distribution, where R was set to be either 0:4 or 0:7. For
responders (Ri D 1), the B1 treatment assignment indicator, Z1i , was generated from a Bernoulli dis-
tribution with 1 D 0:3 or 1 D 0:5. We then defined Z2i D 1  Z1i . For non-responders (Ri D 0),
we generated survival time TNRi from an exponential distribution with mean  D 1, truncated at b D 3.
For responders, a response time, TRi , was generated from an exponential distribution with mean ˛ D 1,
truncated at b˛ D 3:5. For patients receiving maintenance treatment Bk , post-remission survival time
T 
ki
was generated from the relationship T 
ki
D TRi C.ˇ1Cˇ2TRi /uki , for k D 1; 2, where ˇ1 D ˇ2 D 1
and uki are generated from a uniform distribution from 0 to k , where 1 D 1 and 2 D 1:5. Finally,
the survival time for the i th patient is defined as Ti D .1  Ri /TNRi C Ri .TRi C Z1iT 1i C Z2iT 2i /.
Various censoring times, Ci , were taken from a uniform distribution between 0 and V to reflect about
4–40% censoring. For the specific simulations in Tables I and II, V D 7:4 for censoring of 17% when
R D 0:4 and 21% when R D 0:7. Censoring was assumed independent of all other variables. The
observed survival is defined as Ui D min.Ti ; Ci /, and the complete-case indicator is i D I.Ti < Ci /.
We generated 5000 samples of size n (250 and 500) under different scenarios to estimate the median
residual lifetime of DTRs A1B1 and A1B2 at 183.625 and 365.25 days (one half of a year and 1 year).
We summarize the results by presenting the estimate of the MERL with the standard error (SE) esti-
mates using the LDT and sandwich methods, and the corresponding 95% coverage probabilities (CPs)
in Tables I and II.
Table I presents results from the scenarios where patients were assigned to the maintenance treat-
ments, B1 and B2, with equal allocation (1 D 2 D 0:5). We see that the estimator is approximately
unbiased with small observed biases that decrease with increasing sample sizes. The bias is at most 0.7%
for n D 500. Sandwich SEs are slightly larger than the LDT SEs. In most cases, the MERL estimator
with either variance achieved the nominal level of CP (95%).
Scenarios with unequal probability of assignment to maintenance treatments, B1 and B2, are shown
in Table II. Here 1 D 0:3, so 30% of the responders were assigned to B1, while 70% were assigned
to B2. Performance of the estimator, CPs, and SEs remained similar to results in Table I with equal
randomization. With unequal randomization, however, MERL estimators for DTRs corresponding to the
maintenance treatment with higher probability of randomization have smaller SEs compared with that
for DTRs containing maintenance treatment with lower probability of randomization. Specifically, SEs
(LDT or sandwich) for A1B1 were larger than that for A1B2 and larger than the SEs in Table I with 50%
randomization, when 30% of responders were assigned to B1. This is expected because this form of
randomization increases the effective sample size of regimen A1B2 and reduces the number of patients
following DTR A1B1.
As censoring increases, the bias generally increases, as do the SEs for smaller sample sizes (sim-
ulations not shown assessed censoring up to 40%). As censoring increases, the effective sample size
decreases as we have less patients with full information, so a similar pattern is seen between increasing
censoring and decreasing sample size. However, particularly for sample size of 500, the MERL and its
Copyright © 2013 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1503–1513
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Table I. Simulation results of estimation of median residual life at two time points with
k D 0:5.
LDT Sandwich
n R t0 Strategy .t0/ MERL MCSE SE CP SE CP
250 0.4 183.625 A1B1 361 362:4 48:99 47:98 0:943 50:57 0:946
A1B2 304 305:4 42:01 40:81 0:945 42:32 0:946
365.25 A1B1 332 335:4 59:79 57:56 0:941 60:44 0:935
A1B2 282 283:9 53:68 50:70 0:939 52:42 0:928
0.7 183.625 A1B1 459 463:4 59:73 59:13 0:951 62:18 0:951
A1B2 360 364:8 51:55 49:31 0:939 50:96 0:943
365.25 A1B1 406 411:5 70:41 66:88 0:938 70:06 0:929
A1B2 328 332:7 60:61 58:46 0:943 60:26 0:931
500 0.4 183.625 A1B1 361 362:0 34:00 33:94 0:948 35:72 0:955
A1B2 304 305:3 29:75 29:06 0:941 30:08 0:944
365.25 A1B1 332 333:4 41:75 40:66 0:945 42:62 0:949
A1B2 282 283:4 37:29 36:05 0:943 37:19 0:938
0.7 183.625 A1B1 459 460:3 41:86 41:55 0:947 43:65 0:953
A1B2 360 361:5 35:70 34:92 0:945 36:06 0:946
365.25 A1B1 406 407:6 49:38 47:62 0:941 49:82 0:945
A1B2 328 331:1 44:02 41:87 0:938 43:13 0:941
LDT, Lunceford, Davidian and Tsiatis; MERL, median residual life; MCSE, Monte Carlo standard
error; SE, standard error; CP, coverage probability.
Table II. Simulation results of estimation of median residual life at two time points with
k D 0:3.
LDT Sandwich
n R t0 Strategy .t0/ MERL MCSE SE CP SE CP
250 0.4 183.625 A1B1 361 364:7 61:12 59:67 0:945 62:02 0:939
A1B2 304 305:1 37:73 36:17 0:940 37:91 0:949
365.25 A1B1 332 340:8 76:86 71:92 0:935 74:49 0:933
A1B2 282 284:3 46:51 44:46 0:935 46:46 0:931
0.7 183.625 A1B1 459 464:8 78:04 75:57 0:944 78:20 0:937
A1B2 360 361:3 42:87 41:86 0:944 43:90 0:951
365.25 A1B1 406 413:6 91:86 84:93 0:937 87:66 0:915
A1B2 328 331:4 52:56 49:87 0:938 52:13 0:937
500 0.4 183.625 A1B1 361 362:3 41:00 41:80 0:955 43:33 0:949
A1B2 304 304:6 26:49 25:63 0:943 26:84 0:947
365.25 A1B1 332 334:1 52:92 51:10 0:943 52:78 0:934
A1B2 282 282:3 32:91 31:65 0:943 33:04 0:946
0.7 183.625 A1B1 459 462:9 54:44 53:46 0:946 55:24 0:948
A1B2 360 363:1 30:40 29:74 0:940 31:16 0:952
365.25 A1B1 406 409:9 63:50 61:37 0:941 63:25 0:937
A1B2 328 329:4 36:90 35:32 0:936 36:88 0:944
LDT, Lunceford, Davidian and Tsiatis; MERL, median residual life; MCSE, Monte Carlo standard
error; SE, standard error; CP, coverage probability.
variance estimates were similar to those shown in Tables I and II, with CP hovering around 95%. Thus,
increased censoring adds slightly more bias to the MERL estimate, but increasing sample sizes to 500
or more for a trial with two DTRs produces approximately unbiased estimates with adequate coverage.
In both Tables I and II, both the LDT and sandwich variance estimates became closer and closer
to the Monte Carlo variance with increasing sample size implying consistency of both variance estimates.
Overall, the LDT variance estimate was smaller than the sandwich variance estimate, but both provided
similar CP.
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5. Analysis of leukemia Cancer and Leukemia Group B 8923 trial
We applied the proposed methods described in previous sections to estimate the MERL of patients
treated with various treatment regimens from a two-stage randomized clinical trial, shown in Figure 1,
conducted by the CALGB [3, 4]. This double-blinded placebo-controlled trial was designed to examine
the effects of giving infusions of granulocyte-macrophage colony-stimulating factor (GM-CSF)
following induction chemotherapy in AML patients. Patients were initially randomized to GM-CSF
(n=193) or placebo (n=195) following treatment with standard chemotherapy. Patients who achieved
remission and consented to second-stage treatment (79 out of 193 in GM-CSF and 90 out of 195 in the
placebo group) were re-randomized into one of the intensification therapies: cytarabine (denoted by I)
and cytarabine plus mitoxantrone (denoted by II). In this process, 37 patients were assigned to cytara-
bine (I) in the GM-CSF group, whereas 45 patients were assigned to the same maintenance therapy in
the placebo group. The remaining patients in each group received cytarabine plus mitoxantrone (II).
Therefore, there are four possible DTRs in this trial, namely GM-CSF/I, GM-CSF/II, Placebo/I, and
Placebo/II, where for example, ‘GM-CSF/I’ stands for, ‘Add GM-CSF by infusion after chemotherapy
and if the patient achieves remission, follow with maintenance therapy cytarabine, otherwise there is no
further treatment.’
In Table III, we present the MERL estimator (Equation (2)) at specific time points (150, 250, and 350
days) for the DTRs GM-CSF/I, GM-CSF/II, Placebo/I, and Placebo/II and the LDT and sandwich vari-
ance estimates from (Equation (5) and (9)). Similar to the simulation results, the SEs using the sandwich
estimator were slightly larger than those of the LDT estimates. The estimated MERL was smallest for
the GM-CSF/II regimen, whereas, it was the largest for regimen Placebo/II at all three time points. As
the time of interest (t0) increased, median residual lifetimes decreased, except for the DTR Placebo/II
which specified, ‘Do not give GM-CSF after chemotherapy, and when remission is achieved treat with
the combination maintenance therapy of cytarabine plus mitoxantrone, otherwise there is no further
treatment’ We note that only 7.0% of the individuals in this trial were censored, adding to the reliability
of the estimates and SEs.
Estimates of the median residual lifetimes over time are presented in Figure 2 for all four DTRs.
This figure shows the evolution of the MERL over the duration of the trial. For all regimens, the MERL
estimates initially increased, most likely due to the effect of initial treatment. After about 50 days, the
MERL estimates began to decrease for the regimens GM-CSF/I, GM-CSF/II, and Placebo/I. Placebo/II
shows increasing median residual lifetimes throughout much of the trial which is due to the fact that a
number of the patients following this DTR survived for a very long period. This result is consistent with
findings from previous studies based on the mean survival or survival curve ([5, 7]), where it has been
Table III. Estimated median residual lifetime for Cancer and Leukemia
Group B 8923 data at different days.
Variance
Strategy t0 (days) MERL LDT Sandwich
GM-CSF/I 150 312 43:8 45:1
250 265 46:1 47:4
350 235 51:4 52:9
GM-CSF/II 150 285 41:3 42:4
250 238 44:8 46:0
350 182 47:5 48:9
Placebo/I 150 318 44:6 46:8
250 303 50:6 53:1
350 272 56:4 59:2
Placebo/II 150 403 79:1 102:9
250 394 95:8 127:9
350 499 161:0 221:3
MERL, median residual life; LDT, Lunceford, Davidian and Tsiatis; GM-CSF,
granulocyte-macrophage colony-stimulating factor.
Copyright © 2013 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 1503–1513
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Figure 2. Median residual lifetime estimates for CALGB 8923 data with number of the patients at risk for each
dynamic treatment regimen.
shown that infusion with GM-CSF following initial chemotherapy is not beneficial to patients in terms
of overall survival.
6. Discussion
We presented a non-parametric MERL estimator for sequential multiple assignment randomized trials
with two variance estimates. We estimated the MERL indirectly from the estimated survival curve using
inverse probability weighting. The first variance estimate, denoted by LDT, was based on the survival
function variance estimator from Lunceford, Davidian, and Tsiatis [5]. The second variance estimate was
based on the sandwich estimator using the inverse probability estimating equation. The variance estima-
tors differed somewhat with the LDT estimator being slightly more efficient. An important limitation to
these variance estimates is that they require the estimation of the density function in order to estimate
the variance. When the density estimate is not stable, the variance estimates could be less reliable, and
bootstrap samples may be used to estimate the variance. The variance estimates presented, however, are
much easier to implement and generally provide approximately unbiased results.
Results from our simulation study show that the MERL estimator is approximately unbiased. The
LDT variance estimate has slightly smaller SEs than the sandwich estimate, but the MERL with either
variance estimate reaches nominal coverage. It may be of interest to investigate if one particular DTR
is statistically significantly better than the others. To address this, one might simply do a Wald-type test
of linear contrasts of the treatment strategies. Note that the variance of the estimated contrasts must take
into account the dependence of shared-path strategies [24], i.e., regimens that share a common treatment
path. Analytical formulas for covariance between shared-path strategies are not as straightforward and
are currently being studied. A bootstrap approach could be used to estimate the SEs. Future research in
this area might consider including covariates in the estimation process and developing test statistics to
compare median residual lifetimes across different DTRs taking into account the possible shared-path
nature of the regimens.
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